Abstract:Aims: Hearing loss is a common debilitating complication in nasopharyngeal carcinoma (NPC) survivors. The aim of the present study was to investigate the impact of inner ear/cochlear radiation dose and cisplatin use on early and late sensorineural hearing loss (SNHL) in NPC patients treated with radiotherapy alone, concurrent chemoradiation (cCRT) and induction chemotherapy followed by cCRT (iCRT) in the intensity-modulated radiotherapy era. Materials and methods: The study included 81 NPC patients treated with intensity-modulated radiotherapy between 2014 and 2016. Pure tone audiometry was carried out at baseline and follow-up. The effects of cochlear/inner ear radiation and cisplatin doses on early (<12 months) and late (≥24 months) SNHL were analysed using multivariable regression after adjusting for important predictors. Results: In total, 156 ears were examined. In early SNHL (n = 136), cisplatin use predicted the incidence of early high-frequency SHNL (HF-SNHL) (odds ratio 6.4, 95% confidence interval 1.7-23.9, P = 0.005). Ninety ears were analysed for late SNHL (median follow-up 38 months). Inner ear/cochlear radiation and cisplatin doses and better pre-treatment hearing were independent predictors of threshold change at 4 kHz. Every 10 Gy increase in inner ear/cochlear Dmean resulted in 5-dB and 6-dB threshold changes, respectively (cochlear Dmean: B = 0.005, 95% confidence interval 0.0004-0.009, P = 0.031; inner ear Dmean: B = 0.006, 95% confidence interval 0.001-0.010, P = 0.014). Cisplatin use was associated with late HF-SNHL (odds ratio 3.74, 95% confidence interval 1.1-12.3, P = 0.031). In the cCRT and iCRT subgroups, no cisplatin dose-dependent ototoxicity was observed. Severe (≥30 dB) late HF-SNHL occurred in 14% and 25% of the patients when the cochlear dose constraints were 40 Gy and 44 Gy, respectively. The radiotherapy-alone group did not develop severe late HF-SNHL. Conclusion: Cochlear/inner ear radiation dose and cisplatin use showed differential and independent ototoxicity in early and late SNHL. As cochlear/inner ear dose-dependent ototoxicity was demonstrated, the cochlear dose constraint should be as low as reasonably achievable, especially when cisplatin is also administered.

Prenatal Perforation of the Extraperitoneal Part of the Rectum, Associated with a Developmental Defect of the Pelvic Floor

Sensorineural Hearing Loss in Nasopharyngeal Carcinoma Survivors in the Modern Treatment Era - The Early and Late Effects of Radiation and Cisplatin

Dosimetric Parameters Associated with Conductive or Sensorineural Hearing Loss 5 Years after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma

Long-term Efficacy and Adverse Effects of Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma

Current controversies in radiotherapy for nasopharyngeal carcinoma (NPC)

Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost

Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial

Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors

Effects of Dose Limitation and Increased Protective Weight on Dose Distribution in Auditory Organs During Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma

Temporal Lobe Necrosis Following Radiotherapy in Nasopharyngeal Carcinoma: New Insight Into the Management

Long-term Outcomes of Nasopharyngeal Carcinoma Patients with T1-2 Stage in Intensity-Modulated Radiotherapy Era.

Embracing Personalized Strategies in Radiotherapy for Nasopharyngeal Carcinoma: Beyond the Conventional Bounds of Fields and Borders

Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma

Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up

Reducing Target Volumes of Intensity-Modulated Radiotherapy Following Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial

Combinations of radiotherapy with immunotherapy in nasopharyngeal carcinoma

Comprehensive Treatment of Radiation-Induced Lower Cranial Neuropathy in Patients with Nasopharyngcal Carcinoma: a Clinical Analysis

Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality.

A Systematic Review of Proton Therapy for the Management of Nasopharyngeal Cancer

A Study of Middle Ear Function in the Treatment of Nasopharyngeal Carcinoma with IMRT Technique

Intensity-modulated Radiotherapy Combined with Sequential Cisplatin and Fluorouracil Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma